End Stage Renal Disease, Thrombosis
Conditions
Keywords
Hemodialysis
Brief summary
This study evaluates the safety and efficacy of AB002 (E-WE thrombin) in patients with end stage renal disease on chronic hemodialysis. Two dose levels will be evaluated in two cohorts. Within each cohort the patients will be randomized to receive either AB002 (E-WE thrombin) or placebo (at a ratio of 2:1 active: placebo).
Interventions
DRUGAB002 Dose 1
AB002 (E-WE thrombin) 1.5 mcg/kg administered on Day 1 as a single intravenous infusion
DRUGAB002 Dose 2
AB002 (E-WE thrombin) 3.0 mcg/kg administered on Day 1 as a single intravenous infusion
DRUGplacebo
placebo administered on Day 1 as a single intravenous infusion
Sponsors
Celerion
Aronora, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. End Stage Renal Disease (ESRD) maintained on stable outpatient hemodialysis regimen, using an established (\> 3 months) and normally functioning, regular flow, uninfected mature AV fistula (or AV graft) and skin consistent with standard chronic hemodialysis access injuries, and hemodialysis stability defined as Kt/V ≥ 1.2 within 3 months prior to screening at a healthcare center for \> 3 months from screening. 2. On hemodialysis regimen at least 3 times per week for a minimum of 3 hours per dialysis session, using a complication-free well maintained AV fistula (or AV graft), expected and plan to continue this throughout and for at least 3 months beyond the study. 3. Is capable of understanding the written informed consent, provides signed and witnessed written informed consent and agrees to comply with protocol requirements and study related procedures. 4. Willing to be confined to the clinical research unit for the duration of the study, able to comply with all study-related requirements, and able to adhere to study restrictions and visit schedules. 5. Male or female, between 18 and 80 years of age (inclusive) at the time of screening. 6. Body Mass Index (BMI) of ≥ 18 at the time of screening. 7. Considered by the principle investigator (PI) to be clinically stable with respect to underlying ESRD, based on the medical evaluation that includes medical and surgical history, and a complete physical examination including vital sign measurements, electrocardiograms (ECGs), and clinical laboratory and coagulation test results at screening. Repeat assessments are permitted for any laboratory, coagulation, ECG, or vital sign parameter required for enrollment. 8. Female patients must be of non-childbearing potential and must have undergone one of the following sterilization procedures at least 6 months prior to dosing: * hysteroscopic sterilization; * bilateral tubal ligation or bilateral salpingectomy; * hysterectomy; * bilateral oophorectomy; or be postmenopausal with amenorrhea for at least 1 year prior to dosing and follicle stimulating hormone (FSH) serum levels consistent with postmenopausal status as per PI or designee judgment. 9. Male patients must either be sterile (vasectomy with history of a negative sperm count following the procedure); practice total abstinence from sexual intercourse as the preferred lifestyle (periodic abstinence is not acceptable); use a male condom with any sexual activity; or agree to use a birth control method considered to be appropriate by the Investigator from the time of dosing until 90 days after study drug administration. Male patients must agree not to donate sperm for a period of 90 days after study drug administration.
Exclusion criteria
1. Documented history of acute vasoocclusive thrombotic event (acute coronary syndrome, stroke or transient ischemic attack, venous thromboembolic event), or vascular access fistula or AV graft failure in the past 3 months. 2. With the exception of unfractionated heparin during HD that is allowed until study check-in, concomitant or prior use of anticoagulant/antiplatelet agents (e.g., low molecular weight heparins, warfarin, apixaban, bivalirudin, ticagrelor, edoxaban, dabigatran, rivaroxaban, clopidogrel, prasugrel, ticlopidine, eptifibatide, tirofiban, dipyridamole, diclofenac, and all other non steroidal antiinflammatory drugs) that may affect hemostasis for 2 weeks prior to check in on Day -8 and throughout the study. 3. Any clinically significant (CS) concomitant disease or condition (including treatment for such conditions) that, in the opinion of the PI, could either interfere with the study drug, compromise interpretation of study data, or pose an unacceptable risk to the patient. 4. Any other CS abnormalities in laboratory test results at screening or Day * 8 check-in that would, in the opinion of the PI, increase the patient's risk of participation, jeopardize complete participation in the study, or compromise interpretation of study data. 5. Pregnant (positive pregnancy test) at screening or check-in on Day -8. If serum human chorionic gonadotropin (hCG) pregnancy test results are indeterminate, follow-up testing should be performed to determine eligibility. All female patients will not be pregnant and will have a negative pregnancy test at screening and check-in on Day -8, with the following exception: females receiving dialysis with an indeterminate pregnancy test result or persistently low hCG resulting in a false positive pregnancy test may be included in the study at the discretion of the PI. Postmenopausal patients with a result outside the postmenopausal range or an indeterminate pregnancy test will undergo additional testing with FSH to confirm postmenopausal status prior to study enrollment. 6. Treatment with another investigational drug or participation in a device study within 30 days (or 5 half lives, whichever is longer) prior to check-in on Day -8. 7. Acute illness that is considered by the PI to be CS within 2 weeks of check-in on Day 8. 8. Surgery within the past 90 days prior to dosing which in the opinion of the PI or designee is clinically relevant. 9. Currently have established underlying inherited or acquired symptomatic bleeding disorders and/or are at risk for excessive bleeding per PI judgment or current active bleeding (e.g., gastrointestinal, intracranial), aside from minor bleeding from the puncture site on the AV fistula or AV graft, which would be expected to occur during the dialysis procedure, with the following values: * Platelet count \< 100,000 cells/mm3 (if \< 100,000 cells/mm3 but \> 75,000 cells/mm3, with permission of PI and medical monitor) at screening or check-in on Day -8. * INR \> 1.4 at screening or check-in on Day -8 * aPTT up to 1.2 x upper limit of normal (ULN) (if \> 1.2 x ULN and up to \< 1.5 x ULN, with permission of PI and medical monitor) at screening or check-in on Day -8 * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 2 x ULN at screening or check-in on Day -8 * Total bilirubin \> 1.2 x ULN at screening or check-in on Day -8 * Hemoglobin concentration \< 10 g/dL at screening or check-in on Day * 8 10. Seated blood pressure \< 90/40 mmHg at screening and check-in on Day * 8\. 11.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Number of Subjects With Clinically Significant Changes in Urine Leukocyte Esterase Levels and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric). | Study day -8 and 3 | Leukocyte esterase levels in the urine will be evaluated. |
| The Number of Subjects With Clinically Significant Changes in Urine Protein Levels and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric). | Study day -8 and 3 | Protein levels in the urine will be evaluated. |
| The Number of Subjects With Clinically Significant Changes in Urine Glucose Levels and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric). | Study day -8 and 3 | Glucose levels in the urine will be evaluated. |
| The Number of Subjects With Clinically Significant Changes in Urine Ketone Levels and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric). | Study day -8 and 3 | Ketone levels in the urine will be evaluated. |
| The Number of Subjects With Clinically Significant Changes in Urine Bilirubin Levels and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric). | Study day -8 and 3 | Bilirubin levels in the urine will be evaluated. |
| The Number of Subjects With Clinically Significant Changes in Urine Blood Levels and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric). | Study day -8 and 3 | Blood levels in the urine will be evaluated. |
| The Number of Subjects With Clinically Significant Changes in Urine Nitrite Levels and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric). | Study day -8 and 3 | Nitrite levels in the urine will be evaluated. |
| The Number of Subjects With Clinically Significant Changes in Urine Urobilinogen Levels and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric). | Study day -8 and 3 | Urobilinogen levels in the urine will be evaluated. |
| The Number of Subjects That Develop Antibodies to Endogenous Thrombin Will be Summarized Using Frequency Counts (Safety and Tolerability). | Study day 1 pre-dose and study day 14 | Immunogenicity measured by the presence of serum anti-thrombin antibodies in both an ADA screening assay and confirmatory assay. |
| The Number of Subjects With Treatment-emergent Adverse Events (TEAEs) Related to Treatment Will be Summarized Using Frequency Counts (Safety and Tolerability) | 22 days | TEAEs will be determined by physical examination that will include assessment of skin, head, ears, eyes, nose, throat, respiratory system, cardiovascular system, gastrointestinal system, neurological condition, blood and lymphatic systems, and the musculoskeletal system. |
| The Number of TEAEs Related to Treatment Will be Summarized Using Frequency Counts (Safety and Tolerability). | 22 days | TEAEs will be determined by physical examination that will include assessment of skin, head, ears, eyes, nose, throat, respiratory system, cardiovascular system, gastrointestinal system, neurological condition, blood and lymphatic systems, and the musculoskeletal system. |
| The Number of Subjects With Bleeding at the Hemodialysis (HD) Vascular Access Site (Safety and Tolerability) | At each hemodialysis session (non-dose days: study day -7, -5, -2, and 3 and dose day: study day 1) | The number of patients in which clinically relevant and non-major bleeding events occurred from the vascular access site. Bleeding from the access site was assessed immediately following decannulation. Pressure was placed on the access site for 10 min. After 10 minutes, the access site was checked for bleeding. If still bleeding, pressure was applied for another 5 minutes and checked again. This was repeated until hemostasis was achieved and the time to hemostasis was recorded. A time greater than 10 min was considered a non-major bleeding event. |
| The Number of Subjects With Abnormal Electrocardiogram That is Related to Treatment Will be Summarized Using Frequency Counts (Safety and Tolerability). | Study Days -8 (pre-treatment), Day 1, and 3 (post-treatment) | 12-lead electrocardiogram measurement. Abnormal electrocardiogram was determined by the study PI. The result was determined to be treatment related if the abnormal electrocardiogram occurred post-treatment and not pre-treatment. Data from the specified time points (Study Day 1 (0.5h post-dose) and Study Day 3) were combined by adding the number of participants on each Study Day that showed an abnormal electrocardiogram compared to pre-treatment (Study Day -8). |
| The Number of Subjects With Clinically Significant Changes in Body Temperature in Relation to Treatment Will be Assessed. | Study days -7, -5, -2 (pre-treatment), 1 and 3 (post-treatment) | Body temperature will be measured in degrees Celsius. Clinically significant changes in body temperature were determined by the study PI. The result was determined to be treatment related if the change in body temperature occurred post-treatment and not pre-treatment. Data from the specified time points (Study Day 1 (1h post-dose) and Study Day 3) were combined by adding the number of participants on each Study Day that showed a clinically significant change in body temperature compared to pre-treatment (Study Days -7, -5, -2, and 1 (pre-dose)). |
| The Number of Subjects With Clinically Significant Changes in Respiratory Rate and Relation to Treatment Will be Assessed. | Study days -7, -5, -2 (pre-treatment), 1 and 3 (post-treatment) | Respiratory rate will be measured in breaths per minute. Clinically significant changes in respiratory rate were determined by the study PI. The result was determined to be treatment related if the clinically significant changes in respiratory rate occurred post-treatment compared to pre-treatment. Data from the specified time points (Study Day 1 (1h post-dose) and Study Day 3) were combined by adding the number of participants on each Study Day that showed a clinically significant change in respiratory rate compared to pre-treatment (Study Days -7. -5. -2 and 1 (pre-dose)). |
| The Number of Subjects With Clinically Significant Changes in Blood Pressure (Systolic and Diastolic) and Relation to Treatment Will be Assessed. | Study days -7, -5, -2 (pre-treatment), 1 and 3 (post-treatment) | Systolic and diastolic blood pressure will be measured in mmHg. Clinically significant changes in blood pressure were determined by the study PI. The result was determined to be treatment related if the clinically significant changes in blood pressure occurred post-treatment compared to pre-treatment. Data from the specified time points (Study Day 1 (1h post-dose) and Study Day 3) were combined by adding the number of participants on each Study Day that showed a clinically significant change in blood pressure compared to pre-treatment (Study Days -7, -5, -2 and 1 (pre-dose)). |
| The Number of Subjects With Clinically Significant Changes in Heart Rate and Relation to Treatment Will be Assessed. | Study days -7, -5, -2 (pre-treatment), 1 and 3 (post-treatment) | Heart rate will be measured in beats per minute. Clinically significant changes in heart rate were determined by the study PI. The result was determined to be treatment related if the clinically significant changes in heart rate occurred post-treatment compared to pre-treatment. Data from the specified time points (Study Day 1 (1h post-dose) and Study Day 3) were combined by adding the number of participants on each Study Day that showed a clinically significant change in heart rate compared to pre-treatment (Study Days -7, -5, -2 and 1 (pre-dose)). |
| The Number of Subjects With Clinically Significant Changes in Activated Partial Thromboplastin Time (aPTT) and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel. | Study days -7, -5, -2 (pre-treatment), 1 and 3 (post-treatment) | Plasma aPTT will be measured in seconds. Clinically significant changes in aPTT were determined by the study PI. The result was determined to be treatment related if the clinically significant changes in aPTT occurred post-treatment compared to pre-treatment. Data from the specified time points (Study Day 1 and Study Day 3) were combined by adding the number of participants on each Study Day that showed a clinically significant change in aPTT compared to pre-treatment (Study Days -7, -5, -2 and 1 (pre-dose)). |
| The Number of Subjects With Clinically Significant Changes in Prothrombin Time and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel. | Study days -7, -5, -2 (pre-treatment), 1 and 3 (post-treatment) | Prothrombin time will be measured in seconds. Clinically significant changes in prothrombin time were determined by the study PI. The result was determined to be treatment related if the clinically significant changes in prothrombin time occurred post-treatment compared to pre-treatment. Data from the specified time points (Study Day 1 and Study Day 3) were combined by adding the number of participants on each Study Day that showed a clinically significant change in prothrombin time compared to pre-treatment. |
| The Number of Subjects With Clinically Significant Changes in Plasma Fibrinogen and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel. | Study days -7, -5, -2 (pre-treatment), 1 and 3 (post-treatment) | Plasma fibrinogen will be measured in mg/dL. Clinically significant changes in fibrinogen were determined by the study PI. The result was determined to be treatment related if the clinically significant changes in fibrinogen occurred post-treatment compared to pre-treatment. Data from the specified time points (Study Day 1 and Study Day 3, before and after hemodialysis) were combined by adding the number of participants on each Study Day that showed a clinically significant change in fibrinogen compared to pre-treatment (Study Days -7. -5. -2). |
| The Number of Subjects With Clinically Significant Changes in Thrombin Time and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel. | Study days -7, -5, -2 (pre-treatment), 1 and 3 (post-treatment). | Thrombin time will be measured in seconds. Clinically significant changes in thrombin time were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in thrombin time occurred post-treatment compared to pre-treatment. Data from the post-treatment time points (Study Day 1 and Study Day 3, before and after hemodialysis) were combined by adding the number of participants on each Study Day that showed a clinically significant change in prothrombin time compared to pre-treatment. |
| The Number of Subjects With Clinically Significant Changes in Bilirubin (Total and Direct) Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | Study days -8 and 3 | Bilirubin (total and direct) levels in the blood will be measured in mg/dL. Clinically significant changes in bilirubin were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in bilirubin occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in bilirubin compared to pre-treatment (Study Day -8). |
| The Number of Subjects With Clinically Significant Changes in Alkaline Phosphatase Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | Study day -8 and 3 | Alkaline phosphatase levels in the blood will be measured in U/L. Clinically significant changes in alkaline phosphatase were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in alkaline phosphatase occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in alkaline phosphatase compared to pre-treatment (Study Day -8). |
| The Number of Subjects With Clinically Significant Changes in Aspartate Aminotransferase (AST) Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | Study day -8 and 3 | AST levels in the blood will be measured in U/L. Clinically significant changes in aspartate aminotransferase (AST) were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in AST occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in AST compared to pre-treatment (Study Day -8). |
| The Number of Subjects With Clinically Significant Changes in Alanine Aminotransferase (ALT) Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | Study day -8 and 3 | ALT levels in the blood will be measured in U/L. Clinically significant changes in alanine aminotransferase (ALT) were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in ALT occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in ALT compared to pre-treatment (Study Day -8). |
| The Number of Subjects With Clinically Significant Changes in Lactate Dehydrogenase (LDH) Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | Study day -8 and 3 | LDH levels in the blood will be measured in U/L. Clinically significant changes in lactate dehydrogenase (LDH) were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in LDH occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in LDH compared to pre-treatment (Study Day -8). |
| The Number of Subjects With Clinically Significant Changes in Albumin Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | Study day -8 and 3 | Albumin levels in the blood will be measured in g/dL. Clinically significant changes in albumin were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in albumin occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in albumin compared to pre-treatment (Study Day -8). |
| The Number of Subjects With Clinically Significant Changes in Sodium Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | Study day -8 and 3 | Sodium levels will be measured in mEq/L. Clinically significant changes in sodium levels were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in sodium levels occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in sodium levels compared to pre-treatment (Study Day -8). |
| The Number of Subjects With Clinically Significant Changes in Potassium Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | Study days -8 and 3. | Potassium levels will be measured in mmol/L. Clinically significant changes in potassium levels were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in potassium levels occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in potassium levels compared to pre-treatment (Study Day -8). |
| The Number of Subjects With Clinically Significant Changes in Chloride Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | Study day -8 and 3 | Chloride levels will be measured in mEq/L. Clinically significant changes in chloride levels were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in chloride levels occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in chloride levels compared to pre-treatment (Study Day -8). |
| The Number of Subjects With Clinically Significant Changes in Glucose Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | Study day -8 and 3 | Blood glucose levels will be measured in mg/dL. Clinically significant changes in glucose levels were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in glucose occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in glucose compared to pre-treatment (Study Day -8). |
| The Number of Subjects With Clinically Significant Changes in Creatinine Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | Study day -8 and 3 | Creatinine levels will be measured in mg/dL. Clinically significant changes in creatinine levels were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in creatinine levels occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in creatinine compared to pre-treatment (Study Day -8). |
| The Number of Subjects With Clinically Significant Changes in Hemoglobin Levels and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. | Study day -8 and 3 | Hemoglobin levels will be measured in g/dL. Clinically significant changes in hemoglobin were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in hemoglobin occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in hemoglobin compared to pre-treatment (Study Day -8). |
| The Number of Subjects With Clinically Significant Changes in Hematocrit and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. | Study day -8 and 3 | Hematocrit levels will be measured in %. Clinically significant changes in hematocrit were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in hematocrit occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in hematocrit compared to pre-treatment (Study Day -8). |
| The Number of Subjects With Clinically Significant Changes in Total Leukocyte Counts and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. | Study day -8 and 3 | Total leukocyte counts will be measured in 10˄3/uL. Clinically significant changes in total leukocyte count were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in total leukocyte count occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in total leukocyte count compared to pre-treatment (Study Day -8). |
| The Number of Subjects With Clinically Significant Changes in Differential Leukocyte Counts and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. | Study day -8 and 3 | Differential leukocyte counts will be measured in %. Clinically significant changes in differential leukocyte counts were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in differential leukocyte counts occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in differential leukocyte counts compared to pre-treatment (Study Day -8). |
| The Number of Subjects With Clinically Significant Changes in Red Blood Cell Count and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. | Study day -8 and 3 | Red blood cell count will be measured in 10˄6/uL. Clinically significant changes in red blood cell counts were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in red blood cell counts occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in red blood cell counts compared to pre-treatment (Study Day -8). |
| The Number of Subjects With Clinically Significant Changes in Platelet Count and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. | Study days -7, -5, -2, 1, and 3, pre- and post-dialysis. | Platelet count will be measured in 10˄3/uL. Clinically significant changes in platelet count were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in platelet count occurred post-treatment compared to pre-treatment. Data from the post-treatment time points (Study Days 1 and 3) are combined by adding the number of participants on each Study Day that showed a clinically significant change in platelet count post-treatment compared to pre-treatment (Study Days -7, -5, -2). |
| The Number of Subjects With Clinically Significant Changes in Urine pH and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric). | Study day -8 and 3 | pH of the urine will be measured. |
| The Number of Subjects With Clinically Significant Changes in Urine Specific Gravity and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric). | Study day -8 and 3 | Specific gravity of the urine will be evaluated. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hemodialysis Efficiency as Measure by the Frequency of Clotting on the Dialysis Circuit: Venous Chamber (Pharmacodynamic Outcome) | At each hemodialysis session (non-dose days: study day -7, -5, -2, and 3 and dose day: study day 1) | Assessment of thrombus accumulation in the dialysis venous chamber measured by visual inspection. A score ranging from 1-7 is determined by someone blinded to treatment using a Visual Score Assessment of Clotting in the Hemodialysis Circuit: 1- no detectable clotting, 2- presence of fibrous ring or minimum clot affecting less than 5% of chamber space, 3- clot formation, affecting more than 5% but less than 25% of chamber space, 4- clot formation, affecting more than 25% but less than 50% of chamber space, 5- clot formation, affecting more than 50% but less than 75% of chamber space, 6- clot formation, affecting more than 75% of chamber space, and 7- Complete occlusion of chamber. |
| Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels, URR (Pharmacodynamic Outcome). | At each hemodialysis session (non-dose days: study day -7, -5, -2, and 3 and dose day: study day 1) | Assessment of BUN (mg/dL) before and after hemodialysis as urea reduction ratio (URR), %. |
| Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels (Pharmacodynamic Outcome), KtV. | At each hemodialysis session (non-dose days: study day -7, -5, -2, and 3 and dose day: study day 1) | Assessment of BUN (mg/dL) before and after hemodialysis as KtV (mL/min). |
| Hemodialysis Efficiency as Measured by Blood Potassium Levels (Pharmacodynamic Outcome). | At each hemodialysis session (non-dose days: study day -7, -5, -2, and 3 and dose day: study day 1) | Assessment of plasma potassium (mmol/L) before and after hemodialysis. The reduction of plasma potassium is reported as fold change (post-hemodialysis plasma potassium/ pre-hemodialysis plasma potassium). |
| The Effect of a Single Intravenous Dose of E-WE Thrombin on Plasma Activated Protein C-Protein C Inhibitor Complex (APC-PCI) Levels as a Surrogate for Drug Exposure. | Study day 1: (pre-dose, 0.167h, 0.5h, 1h, 2h, 4h, 6h, 24h post-dose) | Plasma APC-PCI (ng/mL) levels will be determined by ELISA. |
| The Number of Subjects That Develop Anti-drug Antibodies Will be Summarized by Frequency Counts. | Study day 1 pre-dose and study day 14 | Plasma anti-drug antibodies will be determined by ELISA. |
| Hemodialysis Efficiency as Measured by Frequency of Clotting on the Dialysis Filters and Circuit (Pharmacodynamic Outcome). | At each hemodialysis session (non-dose days: study day -7, -5, -2, and 3 and dose day: study day 1) | Assessment of thrombus accumulation in the dialyzer cartridge measured by visual inspection. Assessment of thrombus accumulation in the dialysis filter measured by visual inspection. A score ranging from 1-6 is determined by someone blinded to treatment by the Visual Score Assessment of Clotting in the Hemodialysis Circuit scale: 1- no clotting/clean dialyzer or few blood streaks affecting less than 5% of the fibers seen at the surface of the dialyzer, 2- blood streaks affecting more than 5% but less than 25% of the fibers seen at the surface of the dialyzer, 3- blood streaks affecting more than 25% but less than 50% of the fibers seen at the surface of the dialyzer, 4- blood streaks affecting more than 50% but less than 75% of the fibers seen at the surface of the dialyzer, 5- blood streaks affecting more than 75% of the fibers seen at the surface of the dialyzer, and 6- complete occlusion, coagulated filter (treatment cannot continue without replacement of dialyzer). |
Countries
United States
Participant flow
Pre-assignment details
A total of 53 participants were screened for the study, 13 of which did not meet eligibility criteria. The remaining 40 patients were enrolled. Four participants terminated the study prior to randomization either by withdrawing consent or at the PI's discretion. The remining 36 participants were randomized and dosed on Study Day 1.
Participants by arm
| Arm | Count |
|---|---|
| AB002 (E-WE-thrombin) Dose 1 Participants received a single dose of 1.5 mcg/kg E-WE thrombin.
AB002 Dose 1: AB002 (E-WE thrombin) 1.5 mcg/kg administered on Day 1 as a single intravenous infusion | 12 |
| AB002 (E-WE-thrombin) Dose 2 Participants received a single dose of 3.0 mcg/kg E-WE thrombin.
AB002 Dose 2: AB002 (E-WE thrombin) 3.0 mcg/kg administered on Day 1 as a single intravenous infusion | 12 |
| Placebo Participants received a single dose of placebo
placebo: placebo administered on Day 1 as a single intravenous infusion | 12 |
| Total | 36 |
Baseline characteristics
| Characteristic | AB002 (E-WE-thrombin) Dose 1 | Total | Placebo | AB002 (E-WE-thrombin) Dose 2 |
|---|---|---|---|---|
| Age, Continuous | 54.8 years STANDARD_DEVIATION 8.29 | 54.2 years STANDARD_DEVIATION 9.91 | 54.6 years STANDARD_DEVIATION 12.3 | 53.3 years STANDARD_DEVIATION 9.56 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants | 1 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 11 Participants | 35 Participants | 12 Participants | 12 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 11 Participants | 33 Participants | 12 Participants | 10 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 1 Participants | 3 Participants | 0 Participants | 2 Participants |
| Region of Enrollment United States | 12 participants | 36 participants | 12 participants | 12 participants |
| Sex: Female, Male Female | 4 Participants | 10 Participants | 3 Participants | 3 Participants |
| Sex: Female, Male Male | 8 Participants | 26 Participants | 9 Participants | 9 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 12 | 0 / 12 | 0 / 12 |
| other Total, other adverse events | 1 / 12 | 0 / 12 | 1 / 12 |
| serious Total, serious adverse events | 1 / 12 | 0 / 12 | 0 / 12 |
Outcome results
Primary
The Number of Subjects That Develop Antibodies to Endogenous Thrombin Will be Summarized Using Frequency Counts (Safety and Tolerability).
Immunogenicity measured by the presence of serum anti-thrombin antibodies in both an ADA screening assay and confirmatory assay.
Time frame: Study day 1 pre-dose and study day 14
Population: Day 14 sample was not collected from one subject in the 3.0 mcg/kg AB002 group.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects That Develop Antibodies to Endogenous Thrombin Will be Summarized Using Frequency Counts (Safety and Tolerability). | Study day 1 pre-dose | 3 participants |
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects That Develop Antibodies to Endogenous Thrombin Will be Summarized Using Frequency Counts (Safety and Tolerability). | Study day 14 | 2 participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects That Develop Antibodies to Endogenous Thrombin Will be Summarized Using Frequency Counts (Safety and Tolerability). | Study day 1 pre-dose | 5 participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects That Develop Antibodies to Endogenous Thrombin Will be Summarized Using Frequency Counts (Safety and Tolerability). | Study day 14 | 3 participants |
| Placebo | The Number of Subjects That Develop Antibodies to Endogenous Thrombin Will be Summarized Using Frequency Counts (Safety and Tolerability). | Study day 1 pre-dose | 5 participants |
| Placebo | The Number of Subjects That Develop Antibodies to Endogenous Thrombin Will be Summarized Using Frequency Counts (Safety and Tolerability). | Study day 14 | 6 participants |
Primary
The Number of Subjects With Abnormal Electrocardiogram That is Related to Treatment Will be Summarized Using Frequency Counts (Safety and Tolerability).
12-lead electrocardiogram measurement. Abnormal electrocardiogram was determined by the study PI. The result was determined to be treatment related if the abnormal electrocardiogram occurred post-treatment and not pre-treatment. Data from the specified time points (Study Day 1 (0.5h post-dose) and Study Day 3) were combined by adding the number of participants on each Study Day that showed an abnormal electrocardiogram compared to pre-treatment (Study Day -8).
Time frame: Study Days -8 (pre-treatment), Day 1, and 3 (post-treatment)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Abnormal Electrocardiogram That is Related to Treatment Will be Summarized Using Frequency Counts (Safety and Tolerability). | 0 Participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Abnormal Electrocardiogram That is Related to Treatment Will be Summarized Using Frequency Counts (Safety and Tolerability). | 0 Participants |
| Placebo | The Number of Subjects With Abnormal Electrocardiogram That is Related to Treatment Will be Summarized Using Frequency Counts (Safety and Tolerability). | 0 Participants |
Primary
The Number of Subjects With Bleeding at the Hemodialysis (HD) Vascular Access Site (Safety and Tolerability)
The number of patients in which clinically relevant and non-major bleeding events occurred from the vascular access site. Bleeding from the access site was assessed immediately following decannulation. Pressure was placed on the access site for 10 min. After 10 minutes, the access site was checked for bleeding. If still bleeding, pressure was applied for another 5 minutes and checked again. This was repeated until hemostasis was achieved and the time to hemostasis was recorded. A time greater than 10 min was considered a non-major bleeding event.
Time frame: At each hemodialysis session (non-dose days: study day -7, -5, -2, and 3 and dose day: study day 1)
Population: Two patients from the placebo group had catheters as venous access sites and therefore, time to hemostasis could not be evaluated in these pateints.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Bleeding at the Hemodialysis (HD) Vascular Access Site (Safety and Tolerability) | Dosing day hemodialysis session (day 1) | 1 participants |
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Bleeding at the Hemodialysis (HD) Vascular Access Site (Safety and Tolerability) | Pre-dose hemodialysis sessions (days -7, -5, -2) | 3 participants |
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Bleeding at the Hemodialysis (HD) Vascular Access Site (Safety and Tolerability) | Recovery day hemodialysis session (day 3) | 4 participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Bleeding at the Hemodialysis (HD) Vascular Access Site (Safety and Tolerability) | Dosing day hemodialysis session (day 1) | 0 participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Bleeding at the Hemodialysis (HD) Vascular Access Site (Safety and Tolerability) | Pre-dose hemodialysis sessions (days -7, -5, -2) | 2 participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Bleeding at the Hemodialysis (HD) Vascular Access Site (Safety and Tolerability) | Recovery day hemodialysis session (day 3) | 0 participants |
| Placebo | The Number of Subjects With Bleeding at the Hemodialysis (HD) Vascular Access Site (Safety and Tolerability) | Pre-dose hemodialysis sessions (days -7, -5, -2) | 1 participants |
| Placebo | The Number of Subjects With Bleeding at the Hemodialysis (HD) Vascular Access Site (Safety and Tolerability) | Recovery day hemodialysis session (day 3) | 1 participants |
| Placebo | The Number of Subjects With Bleeding at the Hemodialysis (HD) Vascular Access Site (Safety and Tolerability) | Dosing day hemodialysis session (day 1) | 3 participants |
Primary
The Number of Subjects With Clinically Significant Changes in Activated Partial Thromboplastin Time (aPTT) and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.
Plasma aPTT will be measured in seconds. Clinically significant changes in aPTT were determined by the study PI. The result was determined to be treatment related if the clinically significant changes in aPTT occurred post-treatment compared to pre-treatment. Data from the specified time points (Study Day 1 and Study Day 3) were combined by adding the number of participants on each Study Day that showed a clinically significant change in aPTT compared to pre-treatment (Study Days -7, -5, -2 and 1 (pre-dose)).
Time frame: Study days -7, -5, -2 (pre-treatment), 1 and 3 (post-treatment)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Clinically Significant Changes in Activated Partial Thromboplastin Time (aPTT) and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel. | 0 Participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Clinically Significant Changes in Activated Partial Thromboplastin Time (aPTT) and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel. | 0 Participants |
| Placebo | The Number of Subjects With Clinically Significant Changes in Activated Partial Thromboplastin Time (aPTT) and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel. | 0 Participants |
Primary
The Number of Subjects With Clinically Significant Changes in Alanine Aminotransferase (ALT) Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.
ALT levels in the blood will be measured in U/L. Clinically significant changes in alanine aminotransferase (ALT) were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in ALT occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in ALT compared to pre-treatment (Study Day -8).
Time frame: Study day -8 and 3
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Clinically Significant Changes in Alanine Aminotransferase (ALT) Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Clinically Significant Changes in Alanine Aminotransferase (ALT) Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
| Placebo | The Number of Subjects With Clinically Significant Changes in Alanine Aminotransferase (ALT) Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
Primary
The Number of Subjects With Clinically Significant Changes in Albumin Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.
Albumin levels in the blood will be measured in g/dL. Clinically significant changes in albumin were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in albumin occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in albumin compared to pre-treatment (Study Day -8).
Time frame: Study day -8 and 3
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Clinically Significant Changes in Albumin Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Clinically Significant Changes in Albumin Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
| Placebo | The Number of Subjects With Clinically Significant Changes in Albumin Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
Primary
The Number of Subjects With Clinically Significant Changes in Alkaline Phosphatase Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.
Alkaline phosphatase levels in the blood will be measured in U/L. Clinically significant changes in alkaline phosphatase were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in alkaline phosphatase occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in alkaline phosphatase compared to pre-treatment (Study Day -8).
Time frame: Study day -8 and 3
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Clinically Significant Changes in Alkaline Phosphatase Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Clinically Significant Changes in Alkaline Phosphatase Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
| Placebo | The Number of Subjects With Clinically Significant Changes in Alkaline Phosphatase Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
Primary
The Number of Subjects With Clinically Significant Changes in Aspartate Aminotransferase (AST) Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.
AST levels in the blood will be measured in U/L. Clinically significant changes in aspartate aminotransferase (AST) were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in AST occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in AST compared to pre-treatment (Study Day -8).
Time frame: Study day -8 and 3
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Clinically Significant Changes in Aspartate Aminotransferase (AST) Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Clinically Significant Changes in Aspartate Aminotransferase (AST) Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
| Placebo | The Number of Subjects With Clinically Significant Changes in Aspartate Aminotransferase (AST) Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
Primary
The Number of Subjects With Clinically Significant Changes in Bilirubin (Total and Direct) Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.
Bilirubin (total and direct) levels in the blood will be measured in mg/dL. Clinically significant changes in bilirubin were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in bilirubin occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in bilirubin compared to pre-treatment (Study Day -8).
Time frame: Study days -8 and 3
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Clinically Significant Changes in Bilirubin (Total and Direct) Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Clinically Significant Changes in Bilirubin (Total and Direct) Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
| Placebo | The Number of Subjects With Clinically Significant Changes in Bilirubin (Total and Direct) Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
Primary
The Number of Subjects With Clinically Significant Changes in Blood Pressure (Systolic and Diastolic) and Relation to Treatment Will be Assessed.
Systolic and diastolic blood pressure will be measured in mmHg. Clinically significant changes in blood pressure were determined by the study PI. The result was determined to be treatment related if the clinically significant changes in blood pressure occurred post-treatment compared to pre-treatment. Data from the specified time points (Study Day 1 (1h post-dose) and Study Day 3) were combined by adding the number of participants on each Study Day that showed a clinically significant change in blood pressure compared to pre-treatment (Study Days -7, -5, -2 and 1 (pre-dose)).
Time frame: Study days -7, -5, -2 (pre-treatment), 1 and 3 (post-treatment)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Clinically Significant Changes in Blood Pressure (Systolic and Diastolic) and Relation to Treatment Will be Assessed. | 0 Participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Clinically Significant Changes in Blood Pressure (Systolic and Diastolic) and Relation to Treatment Will be Assessed. | 0 Participants |
| Placebo | The Number of Subjects With Clinically Significant Changes in Blood Pressure (Systolic and Diastolic) and Relation to Treatment Will be Assessed. | 1 Participants |
Primary
The Number of Subjects With Clinically Significant Changes in Body Temperature in Relation to Treatment Will be Assessed.
Body temperature will be measured in degrees Celsius. Clinically significant changes in body temperature were determined by the study PI. The result was determined to be treatment related if the change in body temperature occurred post-treatment and not pre-treatment. Data from the specified time points (Study Day 1 (1h post-dose) and Study Day 3) were combined by adding the number of participants on each Study Day that showed a clinically significant change in body temperature compared to pre-treatment (Study Days -7, -5, -2, and 1 (pre-dose)).
Time frame: Study days -7, -5, -2 (pre-treatment), 1 and 3 (post-treatment)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Clinically Significant Changes in Body Temperature in Relation to Treatment Will be Assessed. | 0 Participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Clinically Significant Changes in Body Temperature in Relation to Treatment Will be Assessed. | 0 Participants |
| Placebo | The Number of Subjects With Clinically Significant Changes in Body Temperature in Relation to Treatment Will be Assessed. | 0 Participants |
Primary
The Number of Subjects With Clinically Significant Changes in Chloride Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.
Chloride levels will be measured in mEq/L. Clinically significant changes in chloride levels were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in chloride levels occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in chloride levels compared to pre-treatment (Study Day -8).
Time frame: Study day -8 and 3
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Clinically Significant Changes in Chloride Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Clinically Significant Changes in Chloride Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
| Placebo | The Number of Subjects With Clinically Significant Changes in Chloride Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
Primary
The Number of Subjects With Clinically Significant Changes in Creatinine Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.
Creatinine levels will be measured in mg/dL. Clinically significant changes in creatinine levels were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in creatinine levels occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in creatinine compared to pre-treatment (Study Day -8).
Time frame: Study day -8 and 3
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Clinically Significant Changes in Creatinine Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Clinically Significant Changes in Creatinine Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
| Placebo | The Number of Subjects With Clinically Significant Changes in Creatinine Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
Primary
The Number of Subjects With Clinically Significant Changes in Differential Leukocyte Counts and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.
Differential leukocyte counts will be measured in %. Clinically significant changes in differential leukocyte counts were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in differential leukocyte counts occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in differential leukocyte counts compared to pre-treatment (Study Day -8).
Time frame: Study day -8 and 3
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Clinically Significant Changes in Differential Leukocyte Counts and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. | 0 Participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Clinically Significant Changes in Differential Leukocyte Counts and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. | 0 Participants |
| Placebo | The Number of Subjects With Clinically Significant Changes in Differential Leukocyte Counts and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. | 0 Participants |
Primary
The Number of Subjects With Clinically Significant Changes in Glucose Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.
Blood glucose levels will be measured in mg/dL. Clinically significant changes in glucose levels were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in glucose occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in glucose compared to pre-treatment (Study Day -8).
Time frame: Study day -8 and 3
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Clinically Significant Changes in Glucose Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Clinically Significant Changes in Glucose Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
| Placebo | The Number of Subjects With Clinically Significant Changes in Glucose Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
Primary
The Number of Subjects With Clinically Significant Changes in Heart Rate and Relation to Treatment Will be Assessed.
Heart rate will be measured in beats per minute. Clinically significant changes in heart rate were determined by the study PI. The result was determined to be treatment related if the clinically significant changes in heart rate occurred post-treatment compared to pre-treatment. Data from the specified time points (Study Day 1 (1h post-dose) and Study Day 3) were combined by adding the number of participants on each Study Day that showed a clinically significant change in heart rate compared to pre-treatment (Study Days -7, -5, -2 and 1 (pre-dose)).
Time frame: Study days -7, -5, -2 (pre-treatment), 1 and 3 (post-treatment)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Clinically Significant Changes in Heart Rate and Relation to Treatment Will be Assessed. | 0 Participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Clinically Significant Changes in Heart Rate and Relation to Treatment Will be Assessed. | 0 Participants |
| Placebo | The Number of Subjects With Clinically Significant Changes in Heart Rate and Relation to Treatment Will be Assessed. | 0 Participants |
Primary
The Number of Subjects With Clinically Significant Changes in Hematocrit and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.
Hematocrit levels will be measured in %. Clinically significant changes in hematocrit were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in hematocrit occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in hematocrit compared to pre-treatment (Study Day -8).
Time frame: Study day -8 and 3
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Clinically Significant Changes in Hematocrit and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. | 0 Participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Clinically Significant Changes in Hematocrit and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. | 0 Participants |
| Placebo | The Number of Subjects With Clinically Significant Changes in Hematocrit and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. | 0 Participants |
Primary
The Number of Subjects With Clinically Significant Changes in Hemoglobin Levels and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.
Hemoglobin levels will be measured in g/dL. Clinically significant changes in hemoglobin were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in hemoglobin occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in hemoglobin compared to pre-treatment (Study Day -8).
Time frame: Study day -8 and 3
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Clinically Significant Changes in Hemoglobin Levels and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. | 0 Participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Clinically Significant Changes in Hemoglobin Levels and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. | 0 Participants |
| Placebo | The Number of Subjects With Clinically Significant Changes in Hemoglobin Levels and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. | 0 Participants |
Primary
The Number of Subjects With Clinically Significant Changes in Lactate Dehydrogenase (LDH) Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.
LDH levels in the blood will be measured in U/L. Clinically significant changes in lactate dehydrogenase (LDH) were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in LDH occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in LDH compared to pre-treatment (Study Day -8).
Time frame: Study day -8 and 3
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Clinically Significant Changes in Lactate Dehydrogenase (LDH) Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Clinically Significant Changes in Lactate Dehydrogenase (LDH) Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
| Placebo | The Number of Subjects With Clinically Significant Changes in Lactate Dehydrogenase (LDH) Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
Primary
The Number of Subjects With Clinically Significant Changes in Plasma Fibrinogen and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.
Plasma fibrinogen will be measured in mg/dL. Clinically significant changes in fibrinogen were determined by the study PI. The result was determined to be treatment related if the clinically significant changes in fibrinogen occurred post-treatment compared to pre-treatment. Data from the specified time points (Study Day 1 and Study Day 3, before and after hemodialysis) were combined by adding the number of participants on each Study Day that showed a clinically significant change in fibrinogen compared to pre-treatment (Study Days -7. -5. -2).
Time frame: Study days -7, -5, -2 (pre-treatment), 1 and 3 (post-treatment)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Clinically Significant Changes in Plasma Fibrinogen and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel. | 0 Participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Clinically Significant Changes in Plasma Fibrinogen and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel. | 0 Participants |
| Placebo | The Number of Subjects With Clinically Significant Changes in Plasma Fibrinogen and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel. | 0 Participants |
Primary
The Number of Subjects With Clinically Significant Changes in Platelet Count and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.
Platelet count will be measured in 10˄3/uL. Clinically significant changes in platelet count were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in platelet count occurred post-treatment compared to pre-treatment. Data from the post-treatment time points (Study Days 1 and 3) are combined by adding the number of participants on each Study Day that showed a clinically significant change in platelet count post-treatment compared to pre-treatment (Study Days -7, -5, -2).
Time frame: Study days -7, -5, -2, 1, and 3, pre- and post-dialysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Clinically Significant Changes in Platelet Count and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. | 0 Participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Clinically Significant Changes in Platelet Count and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. | 0 Participants |
| Placebo | The Number of Subjects With Clinically Significant Changes in Platelet Count and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. | 0 Participants |
Primary
The Number of Subjects With Clinically Significant Changes in Potassium Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.
Potassium levels will be measured in mmol/L. Clinically significant changes in potassium levels were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in potassium levels occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in potassium levels compared to pre-treatment (Study Day -8).
Time frame: Study days -8 and 3.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Clinically Significant Changes in Potassium Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Clinically Significant Changes in Potassium Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
| Placebo | The Number of Subjects With Clinically Significant Changes in Potassium Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
Primary
The Number of Subjects With Clinically Significant Changes in Prothrombin Time and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.
Prothrombin time will be measured in seconds. Clinically significant changes in prothrombin time were determined by the study PI. The result was determined to be treatment related if the clinically significant changes in prothrombin time occurred post-treatment compared to pre-treatment. Data from the specified time points (Study Day 1 and Study Day 3) were combined by adding the number of participants on each Study Day that showed a clinically significant change in prothrombin time compared to pre-treatment.
Time frame: Study days -7, -5, -2 (pre-treatment), 1 and 3 (post-treatment)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Clinically Significant Changes in Prothrombin Time and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel. | 0 Participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Clinically Significant Changes in Prothrombin Time and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel. | 0 Participants |
| Placebo | The Number of Subjects With Clinically Significant Changes in Prothrombin Time and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel. | 0 Participants |
Primary
The Number of Subjects With Clinically Significant Changes in Red Blood Cell Count and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.
Red blood cell count will be measured in 10˄6/uL. Clinically significant changes in red blood cell counts were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in red blood cell counts occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in red blood cell counts compared to pre-treatment (Study Day -8).
Time frame: Study day -8 and 3
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Clinically Significant Changes in Red Blood Cell Count and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. | 0 Participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Clinically Significant Changes in Red Blood Cell Count and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. | 0 Participants |
| Placebo | The Number of Subjects With Clinically Significant Changes in Red Blood Cell Count and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. | 0 Participants |
Primary
The Number of Subjects With Clinically Significant Changes in Respiratory Rate and Relation to Treatment Will be Assessed.
Respiratory rate will be measured in breaths per minute. Clinically significant changes in respiratory rate were determined by the study PI. The result was determined to be treatment related if the clinically significant changes in respiratory rate occurred post-treatment compared to pre-treatment. Data from the specified time points (Study Day 1 (1h post-dose) and Study Day 3) were combined by adding the number of participants on each Study Day that showed a clinically significant change in respiratory rate compared to pre-treatment (Study Days -7. -5. -2 and 1 (pre-dose)).
Time frame: Study days -7, -5, -2 (pre-treatment), 1 and 3 (post-treatment)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Clinically Significant Changes in Respiratory Rate and Relation to Treatment Will be Assessed. | 0 Participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Clinically Significant Changes in Respiratory Rate and Relation to Treatment Will be Assessed. | 0 Participants |
| Placebo | The Number of Subjects With Clinically Significant Changes in Respiratory Rate and Relation to Treatment Will be Assessed. | 0 Participants |
Primary
The Number of Subjects With Clinically Significant Changes in Sodium Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.
Sodium levels will be measured in mEq/L. Clinically significant changes in sodium levels were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in sodium levels occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in sodium levels compared to pre-treatment (Study Day -8).
Time frame: Study day -8 and 3
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Clinically Significant Changes in Sodium Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Clinically Significant Changes in Sodium Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
| Placebo | The Number of Subjects With Clinically Significant Changes in Sodium Levels and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel. | 0 Participants |
Primary
The Number of Subjects With Clinically Significant Changes in Thrombin Time and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.
Thrombin time will be measured in seconds. Clinically significant changes in thrombin time were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in thrombin time occurred post-treatment compared to pre-treatment. Data from the post-treatment time points (Study Day 1 and Study Day 3, before and after hemodialysis) were combined by adding the number of participants on each Study Day that showed a clinically significant change in prothrombin time compared to pre-treatment.
Time frame: Study days -7, -5, -2 (pre-treatment), 1 and 3 (post-treatment).
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Clinically Significant Changes in Thrombin Time and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel. | 0 Participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Clinically Significant Changes in Thrombin Time and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel. | 0 Participants |
| Placebo | The Number of Subjects With Clinically Significant Changes in Thrombin Time and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel. | 0 Participants |
Primary
The Number of Subjects With Clinically Significant Changes in Total Leukocyte Counts and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.
Total leukocyte counts will be measured in 10˄3/uL. Clinically significant changes in total leukocyte count were determined by the study PI. The result was determined to be treatment-related if the clinically significant changes in total leukocyte count occurred post-treatment compared to pre-treatment. Data from the post-treatment time point (Study Day 3) is presented as the number of participants that showed a clinically significant change in total leukocyte count compared to pre-treatment (Study Day -8).
Time frame: Study day -8 and 3
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Clinically Significant Changes in Total Leukocyte Counts and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. | 0 Participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Clinically Significant Changes in Total Leukocyte Counts and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. | 0 Participants |
| Placebo | The Number of Subjects With Clinically Significant Changes in Total Leukocyte Counts and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel. | 0 Participants |
Primary
The Number of Subjects With Clinically Significant Changes in Urine Bilirubin Levels and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).
Bilirubin levels in the urine will be evaluated.
Time frame: Study day -8 and 3
Population: All patients on study were anuric.
Primary
The Number of Subjects With Clinically Significant Changes in Urine Blood Levels and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).
Blood levels in the urine will be evaluated.
Time frame: Study day -8 and 3
Population: All patients on study were anuric.
Primary
The Number of Subjects With Clinically Significant Changes in Urine Glucose Levels and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).
Glucose levels in the urine will be evaluated.
Time frame: Study day -8 and 3
Population: All patients on study were anuric.
Primary
The Number of Subjects With Clinically Significant Changes in Urine Ketone Levels and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).
Ketone levels in the urine will be evaluated.
Time frame: Study day -8 and 3
Population: All patients on study were anuric.
Primary
The Number of Subjects With Clinically Significant Changes in Urine Leukocyte Esterase Levels and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).
Leukocyte esterase levels in the urine will be evaluated.
Time frame: Study day -8 and 3
Population: All patients on study were anuric.
Primary
The Number of Subjects With Clinically Significant Changes in Urine Nitrite Levels and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).
Nitrite levels in the urine will be evaluated.
Time frame: Study day -8 and 3
Population: All patients on study were anuric.
Primary
The Number of Subjects With Clinically Significant Changes in Urine pH and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).
pH of the urine will be measured.
Time frame: Study day -8 and 3
Population: All patients on study were anuric.
Primary
The Number of Subjects With Clinically Significant Changes in Urine Protein Levels and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).
Protein levels in the urine will be evaluated.
Time frame: Study day -8 and 3
Population: All patients on study were anuric.
Primary
The Number of Subjects With Clinically Significant Changes in Urine Specific Gravity and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).
Specific gravity of the urine will be evaluated.
Time frame: Study day -8 and 3
Population: All patients on study were anuric.
Primary
The Number of Subjects With Clinically Significant Changes in Urine Urobilinogen Levels and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel (Unless Patient is Anuric).
Urobilinogen levels in the urine will be evaluated.
Time frame: Study day -8 and 3
Population: All patients on study were anuric.
Primary
The Number of Subjects With Treatment-emergent Adverse Events (TEAEs) Related to Treatment Will be Summarized Using Frequency Counts (Safety and Tolerability)
TEAEs will be determined by physical examination that will include assessment of skin, head, ears, eyes, nose, throat, respiratory system, cardiovascular system, gastrointestinal system, neurological condition, blood and lymphatic systems, and the musculoskeletal system.
Time frame: 22 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects With Treatment-emergent Adverse Events (TEAEs) Related to Treatment Will be Summarized Using Frequency Counts (Safety and Tolerability) | 0 Participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects With Treatment-emergent Adverse Events (TEAEs) Related to Treatment Will be Summarized Using Frequency Counts (Safety and Tolerability) | 0 Participants |
| Placebo | The Number of Subjects With Treatment-emergent Adverse Events (TEAEs) Related to Treatment Will be Summarized Using Frequency Counts (Safety and Tolerability) | 0 Participants |
Primary
The Number of TEAEs Related to Treatment Will be Summarized Using Frequency Counts (Safety and Tolerability).
TEAEs will be determined by physical examination that will include assessment of skin, head, ears, eyes, nose, throat, respiratory system, cardiovascular system, gastrointestinal system, neurological condition, blood and lymphatic systems, and the musculoskeletal system.
Time frame: 22 days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of TEAEs Related to Treatment Will be Summarized Using Frequency Counts (Safety and Tolerability). | 0 number of TEAEs related to treatment |
| AB002 (E-WE-thrombin) Dose 2 | The Number of TEAEs Related to Treatment Will be Summarized Using Frequency Counts (Safety and Tolerability). | 0 number of TEAEs related to treatment |
| Placebo | The Number of TEAEs Related to Treatment Will be Summarized Using Frequency Counts (Safety and Tolerability). | 0 number of TEAEs related to treatment |
Secondary
Hemodialysis Efficiency as Measure by the Frequency of Clotting on the Dialysis Circuit: Venous Chamber (Pharmacodynamic Outcome)
Assessment of thrombus accumulation in the dialysis venous chamber measured by visual inspection. A score ranging from 1-7 is determined by someone blinded to treatment using a Visual Score Assessment of Clotting in the Hemodialysis Circuit: 1- no detectable clotting, 2- presence of fibrous ring or minimum clot affecting less than 5% of chamber space, 3- clot formation, affecting more than 5% but less than 25% of chamber space, 4- clot formation, affecting more than 25% but less than 50% of chamber space, 5- clot formation, affecting more than 50% but less than 75% of chamber space, 6- clot formation, affecting more than 75% of chamber space, and 7- Complete occlusion of chamber.
Time frame: At each hemodialysis session (non-dose days: study day -7, -5, -2, and 3 and dose day: study day 1)
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | Hemodialysis Efficiency as Measure by the Frequency of Clotting on the Dialysis Circuit: Venous Chamber (Pharmacodynamic Outcome) | Non-dose days (study days -7, -5, -2, and 3) | 2.99 average visual score of venous chamber | Standard Error 0.36 |
| AB002 (E-WE-thrombin) Dose 1 | Hemodialysis Efficiency as Measure by the Frequency of Clotting on the Dialysis Circuit: Venous Chamber (Pharmacodynamic Outcome) | Dose day (study day 1) | 1.25 average visual score of venous chamber | Standard Error 1.18 |
| AB002 (E-WE-thrombin) Dose 2 | Hemodialysis Efficiency as Measure by the Frequency of Clotting on the Dialysis Circuit: Venous Chamber (Pharmacodynamic Outcome) | Non-dose days (study days -7, -5, -2, and 3) | 3.31 average visual score of venous chamber | Standard Error 0.49 |
| AB002 (E-WE-thrombin) Dose 2 | Hemodialysis Efficiency as Measure by the Frequency of Clotting on the Dialysis Circuit: Venous Chamber (Pharmacodynamic Outcome) | Dose day (study day 1) | 1.58 average visual score of venous chamber | Standard Error 1.23 |
| Placebo | Hemodialysis Efficiency as Measure by the Frequency of Clotting on the Dialysis Circuit: Venous Chamber (Pharmacodynamic Outcome) | Dose day (study day 1) | 3.17 average visual score of venous chamber | Standard Error 0.61 |
| Placebo | Hemodialysis Efficiency as Measure by the Frequency of Clotting on the Dialysis Circuit: Venous Chamber (Pharmacodynamic Outcome) | Non-dose days (study days -7, -5, -2, and 3) | 3.21 average visual score of venous chamber | Standard Error 0.38 |
Secondary
Hemodialysis Efficiency as Measured by Blood Potassium Levels (Pharmacodynamic Outcome).
Assessment of plasma potassium (mmol/L) before and after hemodialysis. The reduction of plasma potassium is reported as fold change (post-hemodialysis plasma potassium/ pre-hemodialysis plasma potassium).
Time frame: At each hemodialysis session (non-dose days: study day -7, -5, -2, and 3 and dose day: study day 1)
Population: In some instances, the pre-and/or post-dialysis values appeared to be switched and were excluded from the summary statistics or a value was missing or not reportable.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | Hemodialysis Efficiency as Measured by Blood Potassium Levels (Pharmacodynamic Outcome). | Post-dose day 3 | 0.72 fold change plasma potassium | Standard Deviation 0.083 |
| AB002 (E-WE-thrombin) Dose 1 | Hemodialysis Efficiency as Measured by Blood Potassium Levels (Pharmacodynamic Outcome). | Pre-dose day -2 | 0.75 fold change plasma potassium | Standard Deviation 0.076 |
| AB002 (E-WE-thrombin) Dose 1 | Hemodialysis Efficiency as Measured by Blood Potassium Levels (Pharmacodynamic Outcome). | Pre-dose day -7 | 0.78 fold change plasma potassium | Standard Deviation 0.066 |
| AB002 (E-WE-thrombin) Dose 1 | Hemodialysis Efficiency as Measured by Blood Potassium Levels (Pharmacodynamic Outcome). | Pre-dose day -5 | 0.72 fold change plasma potassium | Standard Deviation 0.068 |
| AB002 (E-WE-thrombin) Dose 1 | Hemodialysis Efficiency as Measured by Blood Potassium Levels (Pharmacodynamic Outcome). | Post-dose day 1 | 0.73 fold change plasma potassium | Standard Deviation 0.074 |
| AB002 (E-WE-thrombin) Dose 2 | Hemodialysis Efficiency as Measured by Blood Potassium Levels (Pharmacodynamic Outcome). | Pre-dose day -5 | 0.83 fold change plasma potassium | Standard Deviation 0.337 |
| AB002 (E-WE-thrombin) Dose 2 | Hemodialysis Efficiency as Measured by Blood Potassium Levels (Pharmacodynamic Outcome). | Post-dose day 3 | 0.76 fold change plasma potassium | Standard Deviation 0.07 |
| AB002 (E-WE-thrombin) Dose 2 | Hemodialysis Efficiency as Measured by Blood Potassium Levels (Pharmacodynamic Outcome). | Post-dose day 1 | 0.75 fold change plasma potassium | Standard Deviation 0.16 |
| AB002 (E-WE-thrombin) Dose 2 | Hemodialysis Efficiency as Measured by Blood Potassium Levels (Pharmacodynamic Outcome). | Pre-dose day -2 | 0.73 fold change plasma potassium | Standard Deviation 0.116 |
| AB002 (E-WE-thrombin) Dose 2 | Hemodialysis Efficiency as Measured by Blood Potassium Levels (Pharmacodynamic Outcome). | Pre-dose day -7 | 0.75 fold change plasma potassium | Standard Deviation 0.091 |
| Placebo | Hemodialysis Efficiency as Measured by Blood Potassium Levels (Pharmacodynamic Outcome). | Post-dose day 3 | 0.75 fold change plasma potassium | Standard Deviation 0.087 |
| Placebo | Hemodialysis Efficiency as Measured by Blood Potassium Levels (Pharmacodynamic Outcome). | Pre-dose day -7 | 0.71 fold change plasma potassium | Standard Deviation 0.064 |
| Placebo | Hemodialysis Efficiency as Measured by Blood Potassium Levels (Pharmacodynamic Outcome). | Pre-dose day -2 | 0.70 fold change plasma potassium | Standard Deviation 0.099 |
| Placebo | Hemodialysis Efficiency as Measured by Blood Potassium Levels (Pharmacodynamic Outcome). | Post-dose day 1 | 0.68 fold change plasma potassium | Standard Deviation 0.085 |
| Placebo | Hemodialysis Efficiency as Measured by Blood Potassium Levels (Pharmacodynamic Outcome). | Pre-dose day -5 | 0.70 fold change plasma potassium | Standard Deviation 0.068 |
Secondary
Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels (Pharmacodynamic Outcome), KtV.
Assessment of BUN (mg/dL) before and after hemodialysis as KtV (mL/min).
Time frame: At each hemodialysis session (non-dose days: study day -7, -5, -2, and 3 and dose day: study day 1)
Population: In some instances, the pre-and post-dialysis values appeared to be switched and were excluded from the summary statistics or a value was missing or not reportable.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels (Pharmacodynamic Outcome), KtV. | Pre-dose day -7 | 1.411 KtV (mL/min) | Standard Deviation 0.2261 |
| AB002 (E-WE-thrombin) Dose 1 | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels (Pharmacodynamic Outcome), KtV. | Post-dose day 1 | 1.468 KtV (mL/min) | Standard Deviation 0.2542 |
| AB002 (E-WE-thrombin) Dose 1 | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels (Pharmacodynamic Outcome), KtV. | Pre-dose day -2 | 1.372 KtV (mL/min) | Standard Deviation 0.2657 |
| AB002 (E-WE-thrombin) Dose 1 | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels (Pharmacodynamic Outcome), KtV. | Post-dose day 3 | 1.381 KtV (mL/min) | Standard Deviation 0.2437 |
| AB002 (E-WE-thrombin) Dose 1 | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels (Pharmacodynamic Outcome), KtV. | Pre-dose day -5 | 1.436 KtV (mL/min) | Standard Deviation 0.2025 |
| AB002 (E-WE-thrombin) Dose 2 | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels (Pharmacodynamic Outcome), KtV. | Pre-dose day -2 | 1.391 KtV (mL/min) | Standard Deviation 0.2427 |
| AB002 (E-WE-thrombin) Dose 2 | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels (Pharmacodynamic Outcome), KtV. | Pre-dose day -7 | 1.367 KtV (mL/min) | Standard Deviation 0.2597 |
| AB002 (E-WE-thrombin) Dose 2 | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels (Pharmacodynamic Outcome), KtV. | Pre-dose day -5 | 1.343 KtV (mL/min) | Standard Deviation 0.2429 |
| AB002 (E-WE-thrombin) Dose 2 | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels (Pharmacodynamic Outcome), KtV. | Post-dose day 1 | 1.553 KtV (mL/min) | Standard Deviation 0.4112 |
| AB002 (E-WE-thrombin) Dose 2 | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels (Pharmacodynamic Outcome), KtV. | Post-dose day 3 | 1.373 KtV (mL/min) | Standard Deviation 0.2366 |
| Placebo | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels (Pharmacodynamic Outcome), KtV. | Post-dose day 3 | 1.319 KtV (mL/min) | Standard Deviation 0.2908 |
| Placebo | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels (Pharmacodynamic Outcome), KtV. | Post-dose day 1 | 1.418 KtV (mL/min) | Standard Deviation 0.2312 |
| Placebo | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels (Pharmacodynamic Outcome), KtV. | Pre-dose day -7 | 1.392 KtV (mL/min) | Standard Deviation 0.2505 |
| Placebo | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels (Pharmacodynamic Outcome), KtV. | Pre-dose day -2 | 1.388 KtV (mL/min) | Standard Deviation 0.2357 |
| Placebo | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels (Pharmacodynamic Outcome), KtV. | Pre-dose day -5 | 1.470 KtV (mL/min) | Standard Deviation 0.2408 |
Secondary
Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels, URR (Pharmacodynamic Outcome).
Assessment of BUN (mg/dL) before and after hemodialysis as urea reduction ratio (URR), %.
Time frame: At each hemodialysis session (non-dose days: study day -7, -5, -2, and 3 and dose day: study day 1)
Population: In some instances, the pre-and post-dialysis values appeared to be switched and were excluded from the summary statistics or a value was missing or not reportable.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels, URR (Pharmacodynamic Outcome). | Post-dose, day 1 | 70.63 Urea reduction ratio (%) | Standard Deviation 6.955 |
| AB002 (E-WE-thrombin) Dose 1 | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels, URR (Pharmacodynamic Outcome). | Pre-dose, day -2 | 68.51 Urea reduction ratio (%) | Standard Deviation 7.467 |
| AB002 (E-WE-thrombin) Dose 1 | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels, URR (Pharmacodynamic Outcome). | Pre-dose, day -7 | 69.48 Urea reduction ratio (%) | Standard Deviation 5.457 |
| AB002 (E-WE-thrombin) Dose 1 | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels, URR (Pharmacodynamic Outcome). | Pre-dose, day -5 | 70.48 Urea reduction ratio (%) | Standard Deviation 5.709 |
| AB002 (E-WE-thrombin) Dose 1 | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels, URR (Pharmacodynamic Outcome). | Post-dose (recovery), day 3 | 69.09 Urea reduction ratio (%) | Standard Deviation 7.599 |
| AB002 (E-WE-thrombin) Dose 2 | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels, URR (Pharmacodynamic Outcome). | Pre-dose, day -7 | 68.16 Urea reduction ratio (%) | Standard Deviation 6.419 |
| AB002 (E-WE-thrombin) Dose 2 | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels, URR (Pharmacodynamic Outcome). | Pre-dose, day -5 | 68.43 Urea reduction ratio (%) | Standard Deviation 6.646 |
| AB002 (E-WE-thrombin) Dose 2 | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels, URR (Pharmacodynamic Outcome). | Pre-dose, day -2 | 68.62 Urea reduction ratio (%) | Standard Deviation 6.496 |
| AB002 (E-WE-thrombin) Dose 2 | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels, URR (Pharmacodynamic Outcome). | Post-dose, day 1 | 70.61 Urea reduction ratio (%) | Standard Deviation 5.146 |
| AB002 (E-WE-thrombin) Dose 2 | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels, URR (Pharmacodynamic Outcome). | Post-dose (recovery), day 3 | 69.21 Urea reduction ratio (%) | Standard Deviation 6.391 |
| Placebo | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels, URR (Pharmacodynamic Outcome). | Post-dose (recovery), day 3 | 67.08 Urea reduction ratio (%) | Standard Deviation 8.132 |
| Placebo | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels, URR (Pharmacodynamic Outcome). | Post-dose, day 1 | 69.77 Urea reduction ratio (%) | Standard Deviation 6.135 |
| Placebo | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels, URR (Pharmacodynamic Outcome). | Pre-dose, day -7 | 69.68 Urea reduction ratio (%) | Standard Deviation 6.172 |
| Placebo | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels, URR (Pharmacodynamic Outcome). | Pre-dose, day -2 | 68.69 Urea reduction ratio (%) | Standard Deviation 6.849 |
| Placebo | Hemodialysis Efficiency as Measured by Blood Urea Nitrogen (BUN) Levels, URR (Pharmacodynamic Outcome). | Pre-dose, day -5 | 71.44 Urea reduction ratio (%) | Standard Deviation 6.975 |
Secondary
Hemodialysis Efficiency as Measured by Frequency of Clotting on the Dialysis Filters and Circuit (Pharmacodynamic Outcome).
Assessment of thrombus accumulation in the dialyzer cartridge measured by visual inspection. Assessment of thrombus accumulation in the dialysis filter measured by visual inspection. A score ranging from 1-6 is determined by someone blinded to treatment by the Visual Score Assessment of Clotting in the Hemodialysis Circuit scale: 1- no clotting/clean dialyzer or few blood streaks affecting less than 5% of the fibers seen at the surface of the dialyzer, 2- blood streaks affecting more than 5% but less than 25% of the fibers seen at the surface of the dialyzer, 3- blood streaks affecting more than 25% but less than 50% of the fibers seen at the surface of the dialyzer, 4- blood streaks affecting more than 50% but less than 75% of the fibers seen at the surface of the dialyzer, 5- blood streaks affecting more than 75% of the fibers seen at the surface of the dialyzer, and 6- complete occlusion, coagulated filter (treatment cannot continue without replacement of dialyzer).
Time frame: At each hemodialysis session (non-dose days: study day -7, -5, -2, and 3 and dose day: study day 1)
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | Hemodialysis Efficiency as Measured by Frequency of Clotting on the Dialysis Filters and Circuit (Pharmacodynamic Outcome). | Non-dose days (study days -7, -5, -2, and 3) | 2.58 average visual score of dialyzer filter | Standard Error 0.18 |
| AB002 (E-WE-thrombin) Dose 1 | Hemodialysis Efficiency as Measured by Frequency of Clotting on the Dialysis Filters and Circuit (Pharmacodynamic Outcome). | Dose day (study day 1) | 1.50 average visual score of dialyzer filter | Standard Error 0.19 |
| AB002 (E-WE-thrombin) Dose 2 | Hemodialysis Efficiency as Measured by Frequency of Clotting on the Dialysis Filters and Circuit (Pharmacodynamic Outcome). | Non-dose days (study days -7, -5, -2, and 3) | 2.98 average visual score of dialyzer filter | Standard Error 0.44 |
| AB002 (E-WE-thrombin) Dose 2 | Hemodialysis Efficiency as Measured by Frequency of Clotting on the Dialysis Filters and Circuit (Pharmacodynamic Outcome). | Dose day (study day 1) | 2.33 average visual score of dialyzer filter | Standard Error 0.28 |
| Placebo | Hemodialysis Efficiency as Measured by Frequency of Clotting on the Dialysis Filters and Circuit (Pharmacodynamic Outcome). | Non-dose days (study days -7, -5, -2, and 3) | 2.65 average visual score of dialyzer filter | Standard Error 0.25 |
| Placebo | Hemodialysis Efficiency as Measured by Frequency of Clotting on the Dialysis Filters and Circuit (Pharmacodynamic Outcome). | Dose day (study day 1) | 2.50 average visual score of dialyzer filter | Standard Error 0.29 |
Secondary
The Effect of a Single Intravenous Dose of E-WE Thrombin on Plasma Activated Protein C-Protein C Inhibitor Complex (APC-PCI) Levels as a Surrogate for Drug Exposure.
Plasma APC-PCI (ng/mL) levels will be determined by ELISA.
Time frame: Study day 1: (pre-dose, 0.167h, 0.5h, 1h, 2h, 4h, 6h, 24h post-dose)
Population: In some samples the values were missing or not reportable.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Effect of a Single Intravenous Dose of E-WE Thrombin on Plasma Activated Protein C-Protein C Inhibitor Complex (APC-PCI) Levels as a Surrogate for Drug Exposure. | 4h | 58.52 ng/mL | Standard Deviation 26.79 |
| AB002 (E-WE-thrombin) Dose 1 | The Effect of a Single Intravenous Dose of E-WE Thrombin on Plasma Activated Protein C-Protein C Inhibitor Complex (APC-PCI) Levels as a Surrogate for Drug Exposure. | 0.167h | 31.03 ng/mL | Standard Deviation 8.3 |
| AB002 (E-WE-thrombin) Dose 1 | The Effect of a Single Intravenous Dose of E-WE Thrombin on Plasma Activated Protein C-Protein C Inhibitor Complex (APC-PCI) Levels as a Surrogate for Drug Exposure. | pre-dose | 0.1808 ng/mL | Standard Deviation 0.6264 |
| AB002 (E-WE-thrombin) Dose 1 | The Effect of a Single Intravenous Dose of E-WE Thrombin on Plasma Activated Protein C-Protein C Inhibitor Complex (APC-PCI) Levels as a Surrogate for Drug Exposure. | 1h | 62.52 ng/mL | Standard Deviation 24.5 |
| AB002 (E-WE-thrombin) Dose 1 | The Effect of a Single Intravenous Dose of E-WE Thrombin on Plasma Activated Protein C-Protein C Inhibitor Complex (APC-PCI) Levels as a Surrogate for Drug Exposure. | 6h | 11.33 ng/mL | Standard Deviation 7.265 |
| AB002 (E-WE-thrombin) Dose 1 | The Effect of a Single Intravenous Dose of E-WE Thrombin on Plasma Activated Protein C-Protein C Inhibitor Complex (APC-PCI) Levels as a Surrogate for Drug Exposure. | 2h | 57.77 ng/mL | Standard Deviation 25.31 |
| AB002 (E-WE-thrombin) Dose 1 | The Effect of a Single Intravenous Dose of E-WE Thrombin on Plasma Activated Protein C-Protein C Inhibitor Complex (APC-PCI) Levels as a Surrogate for Drug Exposure. | 0.5h | 54.00 ng/mL | Standard Deviation 21.03 |
| AB002 (E-WE-thrombin) Dose 1 | The Effect of a Single Intravenous Dose of E-WE Thrombin on Plasma Activated Protein C-Protein C Inhibitor Complex (APC-PCI) Levels as a Surrogate for Drug Exposure. | 24h | 0.2808 ng/mL | Standard Deviation 0.9728 |
| AB002 (E-WE-thrombin) Dose 2 | The Effect of a Single Intravenous Dose of E-WE Thrombin on Plasma Activated Protein C-Protein C Inhibitor Complex (APC-PCI) Levels as a Surrogate for Drug Exposure. | 2h | 95.92 ng/mL | Standard Deviation 36.5 |
| AB002 (E-WE-thrombin) Dose 2 | The Effect of a Single Intravenous Dose of E-WE Thrombin on Plasma Activated Protein C-Protein C Inhibitor Complex (APC-PCI) Levels as a Surrogate for Drug Exposure. | 6h | 13.80 ng/mL | Standard Deviation 5.383 |
| AB002 (E-WE-thrombin) Dose 2 | The Effect of a Single Intravenous Dose of E-WE Thrombin on Plasma Activated Protein C-Protein C Inhibitor Complex (APC-PCI) Levels as a Surrogate for Drug Exposure. | 24h | 0.4067 ng/mL | Standard Deviation 0.9562 |
| AB002 (E-WE-thrombin) Dose 2 | The Effect of a Single Intravenous Dose of E-WE Thrombin on Plasma Activated Protein C-Protein C Inhibitor Complex (APC-PCI) Levels as a Surrogate for Drug Exposure. | pre-dose | 1.447 ng/mL | Standard Deviation 1.749 |
| AB002 (E-WE-thrombin) Dose 2 | The Effect of a Single Intravenous Dose of E-WE Thrombin on Plasma Activated Protein C-Protein C Inhibitor Complex (APC-PCI) Levels as a Surrogate for Drug Exposure. | 0.167h | 54.29 ng/mL | Standard Deviation 18.67 |
| AB002 (E-WE-thrombin) Dose 2 | The Effect of a Single Intravenous Dose of E-WE Thrombin on Plasma Activated Protein C-Protein C Inhibitor Complex (APC-PCI) Levels as a Surrogate for Drug Exposure. | 0.5h | 97.01 ng/mL | Standard Deviation 31.41 |
| AB002 (E-WE-thrombin) Dose 2 | The Effect of a Single Intravenous Dose of E-WE Thrombin on Plasma Activated Protein C-Protein C Inhibitor Complex (APC-PCI) Levels as a Surrogate for Drug Exposure. | 1h | 103.9 ng/mL | Standard Deviation 37.62 |
| AB002 (E-WE-thrombin) Dose 2 | The Effect of a Single Intravenous Dose of E-WE Thrombin on Plasma Activated Protein C-Protein C Inhibitor Complex (APC-PCI) Levels as a Surrogate for Drug Exposure. | 4h | 80.38 ng/mL | Standard Deviation 33.06 |
| Placebo | The Effect of a Single Intravenous Dose of E-WE Thrombin on Plasma Activated Protein C-Protein C Inhibitor Complex (APC-PCI) Levels as a Surrogate for Drug Exposure. | 6h | 2.740 ng/mL | Standard Deviation 2.168 |
| Placebo | The Effect of a Single Intravenous Dose of E-WE Thrombin on Plasma Activated Protein C-Protein C Inhibitor Complex (APC-PCI) Levels as a Surrogate for Drug Exposure. | 1h | 0.7736 ng/mL | Standard Deviation 1.842 |
| Placebo | The Effect of a Single Intravenous Dose of E-WE Thrombin on Plasma Activated Protein C-Protein C Inhibitor Complex (APC-PCI) Levels as a Surrogate for Drug Exposure. | 0.5h | 0.4310 ng/mL | Standard Deviation 1.363 |
| Placebo | The Effect of a Single Intravenous Dose of E-WE Thrombin on Plasma Activated Protein C-Protein C Inhibitor Complex (APC-PCI) Levels as a Surrogate for Drug Exposure. | 4h | 6.094 ng/mL | Standard Deviation 5.036 |
| Placebo | The Effect of a Single Intravenous Dose of E-WE Thrombin on Plasma Activated Protein C-Protein C Inhibitor Complex (APC-PCI) Levels as a Surrogate for Drug Exposure. | pre-dose | 0.9508 ng/mL | Standard Deviation 1.885 |
| Placebo | The Effect of a Single Intravenous Dose of E-WE Thrombin on Plasma Activated Protein C-Protein C Inhibitor Complex (APC-PCI) Levels as a Surrogate for Drug Exposure. | 24h | 1.962 ng/mL | Standard Deviation 2.034 |
| Placebo | The Effect of a Single Intravenous Dose of E-WE Thrombin on Plasma Activated Protein C-Protein C Inhibitor Complex (APC-PCI) Levels as a Surrogate for Drug Exposure. | 2h | 2.441 ng/mL | Standard Deviation 3.78 |
| Placebo | The Effect of a Single Intravenous Dose of E-WE Thrombin on Plasma Activated Protein C-Protein C Inhibitor Complex (APC-PCI) Levels as a Surrogate for Drug Exposure. | 0.167h | 0.2480 ng/mL | Standard Deviation 0.7842 |
Secondary
The Number of Subjects That Develop Anti-drug Antibodies Will be Summarized by Frequency Counts.
Plasma anti-drug antibodies will be determined by ELISA.
Time frame: Study day 1 pre-dose and study day 14
Population: Day 14 sample was not collected from one participant in the 3.0 mcg/kg AB002 group.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects That Develop Anti-drug Antibodies Will be Summarized by Frequency Counts. | Study day 1 pre-dose | 0 Participants |
| AB002 (E-WE-thrombin) Dose 1 | The Number of Subjects That Develop Anti-drug Antibodies Will be Summarized by Frequency Counts. | Study day 14 post-dose | 0 Participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects That Develop Anti-drug Antibodies Will be Summarized by Frequency Counts. | Study day 1 pre-dose | 1 Participants |
| AB002 (E-WE-thrombin) Dose 2 | The Number of Subjects That Develop Anti-drug Antibodies Will be Summarized by Frequency Counts. | Study day 14 post-dose | 1 Participants |
| Placebo | The Number of Subjects That Develop Anti-drug Antibodies Will be Summarized by Frequency Counts. | Study day 1 pre-dose | 1 Participants |
| Placebo | The Number of Subjects That Develop Anti-drug Antibodies Will be Summarized by Frequency Counts. | Study day 14 post-dose | 0 Participants |